Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey
| Autor: | Giovanni Luca Ceresoli, Paolo Andrea Zucali, G. Michetti, M. Lo Dico, Alessandro Follador, Laura Giordano, Elena Lorenzi, F. De Vincenzo, Marcello Tiseo, Matteo Perrino, Anna Moretti, Marina Chiara Garassino, Gabriella Farina, Matteo Simonelli, Elena Collovà, Armando Santoro |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology Adult Male Mesothelioma Cancer Research medicine.medical_specialty Guanine medicine.medical_treatment Pleural Neoplasms Platinum Compounds Pemetrexed Glutamates Internal medicine Antineoplastic Combined Chemotherapy Protocols Clinical endpoint Medicine Humans Progression-free survival Survival rate Aged Retrospective Studies Aged 80 and over Chemotherapy business.industry Retrospective cohort study Middle Aged medicine.disease Surgery Clinical trial Survival Rate Treatment Outcome Multivariate Analysis Female Cisplatin business medicine.drug |
| Zdroj: | Lung cancer (Amsterdam, Netherlands). 75(3) |
| ISSN: | 1872-8332 |
| Popis: | The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered, but the optimal treatment has not been defined yet. The aim of this study was to evaluate the clinical outcomes of SL-therapy in a series of MPM-patients included in a retrospective multicenter database. Clinical records of MPM-patients who received SL-treatment from 1996 to 2008 were reviewed. Study endpoints were response, overall-survival (OS), and progression-free-survival (PFS) for SL, stratified for patient characteristics, FL-outcomes, and type of SL. Out of 423 patients, 181 with full clinical data were identified. Patients' characteristics: median-age 64 years (range: 36-85); male gender 115 (63.5%); good EORTC-score 109 (60.2%); epithelial histology 135 (74.6%). After FL, 147 (81.2%) patients achieved disease-control (DC) and 45 had a time-to-progression≥12 months (TTP≥12). After SL, 95 patients (52.6%) achieved DC (21 response; 74 stable-disease); median PFS and OS were 4.3 and 8.7 months, respectively. According to multivariate analysis, DC after SL-therapy was significantly related to pemetrexed-based treatment (OR: 2.46; p=0.017) and FL-TTP≥12 (OR: 3.50; p=0.006). PFS was related to younger age ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect